Teva Announces 2026 Launch for 'Night And Day' Olanzapine Long-Acting Injectable

At the J.P. Morgan Healthcare Conference in San Francisco, Teva has provided a timeline for its much-talked-about long-acting injectable olanzapine candidate, after wrapping up a Phase III clinical trial with data that the firm believes will give it a major advantage over its competitors. The product, dubbed 'Night And Day', is set for a 2026 launch, marking a significant milestone in the treatment of conditions requiring long-acting antipsychotic medication. Teva's announcement underscores the company's commitment to advancing psychiatric treatment options and its confidence in the efficacy and market potential of its olanzapine formulation.